Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Adv Drug Deliv Rev. 2016 Jan 27;99(Pt A):2–11. doi: 10.1016/j.addr.2016.01.009

Fig. 1.

Fig. 1

Systemic and local anti-inflammatory effects of PtdSer-based carriers. a) PtdSer-liposomes (PSL) exhibit systemic anti-inflammatory actions by means of inhibition of antigen presentation by dendritic cells (and possibly monocytes/macrophages) and inhibit T-lymphocyte proliferation in Th1 immune response. This is believed to be dependent on levels of transforming growth factor beta-1 (TGF-β1). Whether PSL directly modulate the function of dendritic cells in this process is not clear. b) PSL acted in various phagocytic and non-phagocytic cell types and elicited anti-inflammatory response. Some specific effects were also noted as indicated.